Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14670427 | 0.87 | BRD4 (0.35) | BRD4NR3C2NR3C1PGR | |
| SCHEMBL14822882 | 0.86 | BRD4 (0.33) | BRD4NR3C2 | |
| SCHEMBL12081744 | 0.83 | NR3C2 (0.47) | BRD4NR3C2 | |
| SCHEMBL14670458 | 0.80 | BRD4 (0.32) | BRD4 | |
| SCHEMBL14670257 | 0.76 | BRD4 (0.34) | BRD4NR3C2NR3C1PGR | |
| SCHEMBL14822873 | 0.75 | BRD4 (0.33) | BRD4NR3C2NR3C1PGR | |
| SCHEMBL14670460 | 0.74 | MAPT (0.31) | — | |
| SCHEMBL3023124 | 0.70 | NR3C2 (0.47) | BRD4NR3C2 | |
| SCHEMBL3011701 | 0.70 | NR3C2 (0.45) | BRD4NR3C2PGR | |
| SCHEMBL13234996 | 0.70 | BRD4 (0.31) | BRD4NR3C2NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8410166-B2 | Fused bicyclic compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | TAKAHASHI YOICHI (JP) | 2013-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130029979-A1 | FUSED BICYCLIC COMPOUND | NR3C2, NR3C1, MC2R | BRD4 112/4885NR3C2 1/4885NR3C1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.